Every lot is tried & tested in a relevant biological assay.
- Cardoso, F. C. et al. (2021) Pain 162, 569.
- Alomone Labs µ/ω-TRTX-Tap1a inhibits NaV1.7 channel currents in stably transfected HEK293 cellsA. Representative time course (n=6) of µ/ω-TRTX-Tap1a (#STT-600) inhibition of NaV1.7 channels current. Membrane potential was held at -100 mV, current was elicited by a 10 ms voltage step to 0 mV every 5 sec, and significantly inhibited by application of 100 nM
B. Superimposed traces of NaV1.7 channel currents in the absence (control) and presence (green) of 100 nM µ/ω-TRTX-Tap1a (taken from the recording in A).
- Cardoso, F. C. et al. (2021) Pain 162, 569.
- Lory, P. et al. (2020) Pflugers Arch – Eur. J. Physiol. 472, 831.
- Pan, C. et al. (2021) Curr. Med. Sci. 41, 680.
- Candelas, M. et al. (2019) Sci. Rep. 9, 3112.
- Dongol, Y. et al. (2019) Toxins 11, 626.
- Reynolds, C. et al. (2020) Eur. J. Paediatr. Neurol. 24, 117.
µ/ω-TRTX-Tap1a (Tap1a) is a 35 amino acid peptidyl toxin originally isolated from the venom of the tarantula, Theraphosa apophysis. Tap1a inhibits voltage-gated sodium (NaV) and voltage-gated calcium (CaV)3 channels by inducing a hyperpolarizing shift in both voltage-dependent activation and steady state inactivation1. Tap1a specifically inhibits NaV1.7, NaV1.2, and CaV3.1 with nanomolar potency and NaV1.3, NaV1.6, NaV1.1, and CaV3.2 at low micromolar concentrations1. These ion channels participate in neuron polarization, transmission of somatosensory signals, as well as neuronal cell differentiation, death, and survival. Thus, they are involved in many diseases, including pain disorders, epilepsy, and age-related neurodegeneration.
Spider peptides modulate an array of ion channels and receptor proteins. Knottins, which are a subtype of spider peptides, are also referred to as inhibitor cystine knot (ICK) peptides. ICK peptides harbor a disulfide-rich structural motif that forms a “knot”, which confers high structural, thermal, and proteolytic stability. The modelled structure of Tap1a revealed an ICK fold typical of spider venom peptides, as well as a hydrophobic patch involved in the binding of spider venom peptides to CaV3 and NaV channels1.
CaV3 are T-type, low voltage-gated calcium channels. Their electrophysiological properties include low voltage thresholds for activation and inactivation, rapid inactivation, and rebound bursting. These properties are responsible for the CaV3-mediated fine-tuned regulation of neuronal excitability in both the central nervous system (CNS) and peripheral nervous system (PNS)2.
CaV3.1 is highly expressed in the brain amygdala, subthalamic nuclei, cerebellum, and thalamus. In contrast, CaV3.1 is only moderately expressed in the heart. CaV3.1 participates in neuron polarization, synaptic transmission, as well as neuronal cell differentiation, death, and survival. CaV3.1 was implicated in the process of age-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease3. Moreover, mutations in CaV3.1 have been shown to induce cerebellar ataxia. CaV3.2 channels are expressed in the thalamus where they play a role in the pathophysiology of epilepsy. In addition, the constitutive deletion of the CaV3.2 gene alleviates acute pain, inflammatory pain, and chronic visceral pain in mice4.
NaV1.1–1.9 are voltage-gated sodium channels. They open upon depolarization of the membrane and inactivate rapidly before returning to the closed state upon membrane hyperpolarization. The rapid influx of Na+ ions is vital to the generation and propagation of action potential (AP) as well as the transmission of somatosensory signals.
NaV1.7 is expressed in the PNS, dorsal root ganglia neurons, visceral sensory neurons, olfactory sensory neurons, trigeminal ganglia, and sympathetic neurons. NaV1.7 gain-of-function mutations have been identified in patients with various pain disorders, such as inherited erythromelalgia (IEM), paroxysmal extreme pain disorder (PEPD), small fiber neuropathy (SFN), and painful diabetic peripheral neuropathy5.
NaV1.2 is abundantly expressed at the nodes of Ranvier and in the axon initial segment (AIS) during early development. NaV1.2 plays a dominant role in the initiation and propagation of APs. In mature neurons, NaV1.6 takes the role of AP initiation, and NaV1.2 merely augments APs. Pathogenic variants of NaV1.2 are common causes of neurodevelopmental disorders such as episodic ataxia, schizophrenia, autism spectrum disorder, and intellectual disability with and without seizures6.
Widget not in any sidebars
µ/ω-TRTX-Tap1a (#STT-600) is a highly pure, synthetic, and biologically active peptide toxin.
- Anti-CACNA1G (CaV3.1) Antibody (#ACC-021)
- Anti-CACNA1G (CaV3.1)-ATTO Fluor-594 Antibody (#ACC-021-AR)
- Anti-CaV3.2 (CACNA1H) Antibody (#ACC-025)
- Anti-NaV1.7 (SCN9A) (extracellular) Antibody (#ASC-027)
- Anti-NaV1.7 (SCN9A) Antibody (#ASC-008)
- Anti-NaV1.7 (SCN9A)-ATTO Fluor-633 Antibody (#ASC-008-FR)
- Anti-SCN2A (NaV1.2) Antibody (#ASC-002)
- Anti-SCN2A (NaV1.2)-ATTO Fluor-594 Antibody (#ASC-002-AR)
- Guinea pig Anti-NaV1.7 (SCN9A) Antibody (#ASC-008-GP (formerly AGP-057))
- Guinea pig Anti-SCN2A (NaV1.2) Antibody (#ASC-002-GP (formerly AGP-026))
Explorer kits & Research packs
- NaV Channel Activator Explorer Kit (#EK-203)
- NaV Channel Blockers for Pain Research Explorer Kit (#EK-375)
- NaV Channel Antibodies for Pain Research Explorer Kit (#AK-365)
- NaV1.2 Channel Basic Research Pack (#ESB-002)
- T-Type CaV Channel Blocker Explorer Kit (#EK-111)
- TTX-Sensitive NaV Channel Blocker Explorer Kit (#EK-105)